WEBULL
News
PLX
2.920
+8.15%
0.220
Protalix Highlights Positive EMA Opinion on Elfabrio Dosing
TipRanks · 12h ago
Weekly Report: what happened at PLX last week (0202-0206)?
Weekly Report · 3d ago
Analysts Are Bullish on Top Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks · 02/03 11:30
Weekly Report: what happened at PLX last week (0126-0130)?
Weekly Report · 02/02 09:37
A March Decision That Could Change Protalix BioTherapeutics Outlook
Seeking Alpha · 02/02 02:27
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy
Seeking Alpha · 01/30 17:53
Protalix Wins EMA Panel Backing for New Elfabrio Dosing
TipRanks · 01/30 15:28
Protalix, Chiesi Global: CHMP issues positive opinion for Elfabrio dosing
TipRanks · 01/30 14:56
Chiesi Group's Unit And Protalix BioTherapeutics Say CHMP Of EMA Issues Positive Opinion Recommending Approval Of 2mg/Kg E4W Dosing Regimen For Elfabrio In Fabry Disease Adult Patients Stable With ERT Treatment
Benzinga · 01/30 14:51
Weekly Report: what happened at PLX last week (0119-0123)?
Weekly Report · 01/26 09:38
Weekly Report: what happened at PLX last week (0112-0116)?
Weekly Report · 01/19 09:41
Weekly Report: what happened at PLX last week (0105-0109)?
Weekly Report · 01/12 09:40
Protalix outlines 2026 rare-disease growth and pipeline strategy
TipRanks · 01/05 12:19
Protalix Bets on Gout and Rare Kidney Diseases as It Eyes New Drug Launches in 2026
Benzinga · 01/05 11:55
Protalix BioTherapeutics Letter to Stockholders
PR Newswire · 01/05 11:50
Weekly Report: what happened at PLX last week (1229-0102)?
Weekly Report · 01/05 09:38
Weekly Report: what happened at PLX last week (1222-1226)?
Weekly Report · 12/29/2025 09:37
Top Executive Makes Bold Insider Move on Protalix Stock
TipRanks · 12/24/2025 02:01
BioMarin: Amicus Buyout Sparks My Enthusiasm
Seeking Alpha · 12/22/2025 20:15
Weekly Report: what happened at PLX last week (1215-1219)?
Weekly Report · 12/22/2025 09:36
More
Webull provides a variety of real-time PLX stock news. You can receive the latest news about Protalix Biother through multiple platforms. This information may help you make smarter investment decisions.
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.